
|Articles|September 1, 2007
- Volume 0 0
WORLD HEALTH ORGANIZATION STUDIES TRAVEL RISKS
Author(s)Anna D. Garrett, PharmD, BCPS, CPP
Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.
Advertisement
In 2001, the World Health Organization (WHO) began a 2-phase project called the WHO Research Into Global Hazards ofTravel (WRIGHT) Project. The objectives of the project were toconfirm that the risk of venous thromboembolism (VTE) isincreased by air travel and to determine the magnitude of risk,the effect of other factors on the risk, and the effect of preventivemeasures on risk.
The key findings of the WRIGHT Phase I report include the following:
- The risk of VTE roughly doubles with flights greater than 4 hours and increaseswith longer flights or repeated flights within a short period of time.
- Overall, the absolute risk of VTE appears to be about 1 in 6000 healthy individuals,but the risk is primarily concentrated in patients with hypercoagulable conditions,those using birth control pills, or those who have other risk factors such asobesity, extremes of height (less than 5?2? or greater than 6?2?), older age, and cardiovasculardisease.
- The VTE risk is greatest immediately following a flight, but some risk persistsfor several weeks afterward.
Articles in this issue
about 19 years ago
Calming the Symptoms of Menopauseabout 19 years ago
Zoster Vaccineabout 19 years ago
pharmacy TECHNOLOGY productsabout 19 years ago
health-systems PRODUCT newsabout 19 years ago
can you READ these Rxs?about 19 years ago
can you READ these Rxs?about 19 years ago
Generic Times Product Newsabout 19 years ago
compounding HOTLINEabout 19 years ago
Human HRT Leads Compounding Renaissanceabout 19 years ago
Prescription-overdose Deaths Surpass Car-accident DeathsAdvertisement
Related to this article

OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.

Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.

The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.

Across every setting, the pharmacist's role is to build reliable systems around patients so stroke prevention remains safe and sustainable across the care continuum.

Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.

Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.

Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
4
The Most Accessible Healthcare Professional—But Accessible to Whom?
5
